Melatonin protects against oxidative stress caused by δ-aminolevulinic acid

Implications for cancer reduction

Malgorzata Karbownik, Russel J Reiter

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

δ-Aminolevulinic acid (ALA) is a precursor of haem. The increased concentration of ALA is typically related to acute intermittent porphyria, hereditary tyrosinemia, and lead poisoning. δ-Aminolevulinic acid produced in excess accumulates in a number of organs, causes oxidative damage, and often leads to cancer. Melatonin (N-acetyl-5-methoxytryptamine) is a well-known antioxidant, free radical scavenger, and exhibits anticarcinogenic properties. It protects DNA, lipids, and proteins from oxidative damage. The protective effects of melatonin against ALA-induced oxidation of guanine bases, lipid peroxidation, and alterations in membrane fluidity in several organs have been documented. There is an inverse relationship between melatonin and ALA concentrations in both experimental and clinical conditions of porphyria. The marked efficacy of melatonin in protecting against ALA-related oxidative stress, its oncostatic properties, and low toxicity constitute reasons to consider the use of this indoleamine as a co-treatment in patients suffering from disturbances related to ALA accumulation.

Original languageEnglish (US)
Pages (from-to)276-286
Number of pages11
JournalCancer Investigation
Volume20
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Aminolevulinic Acid
Melatonin
Oxidative Stress
Neoplasms
5-Methoxytryptamine
Tyrosinemias
Acute Intermittent Porphyria
Porphyrias
Lead Poisoning
Free Radical Scavengers
Membrane Fluidity
Guanine
Heme
Lipid Peroxidation
Antioxidants
Lipids
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Melatonin protects against oxidative stress caused by δ-aminolevulinic acid : Implications for cancer reduction. / Karbownik, Malgorzata; Reiter, Russel J.

In: Cancer Investigation, Vol. 20, No. 2, 2002, p. 276-286.

Research output: Contribution to journalArticle

@article{ca13584a661f405dbfb92e10d7904198,
title = "Melatonin protects against oxidative stress caused by δ-aminolevulinic acid: Implications for cancer reduction",
abstract = "δ-Aminolevulinic acid (ALA) is a precursor of haem. The increased concentration of ALA is typically related to acute intermittent porphyria, hereditary tyrosinemia, and lead poisoning. δ-Aminolevulinic acid produced in excess accumulates in a number of organs, causes oxidative damage, and often leads to cancer. Melatonin (N-acetyl-5-methoxytryptamine) is a well-known antioxidant, free radical scavenger, and exhibits anticarcinogenic properties. It protects DNA, lipids, and proteins from oxidative damage. The protective effects of melatonin against ALA-induced oxidation of guanine bases, lipid peroxidation, and alterations in membrane fluidity in several organs have been documented. There is an inverse relationship between melatonin and ALA concentrations in both experimental and clinical conditions of porphyria. The marked efficacy of melatonin in protecting against ALA-related oxidative stress, its oncostatic properties, and low toxicity constitute reasons to consider the use of this indoleamine as a co-treatment in patients suffering from disturbances related to ALA accumulation.",
author = "Malgorzata Karbownik and Reiter, {Russel J}",
year = "2002",
doi = "10.1081/CNV-120001154",
language = "English (US)",
volume = "20",
pages = "276--286",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Melatonin protects against oxidative stress caused by δ-aminolevulinic acid

T2 - Implications for cancer reduction

AU - Karbownik, Malgorzata

AU - Reiter, Russel J

PY - 2002

Y1 - 2002

N2 - δ-Aminolevulinic acid (ALA) is a precursor of haem. The increased concentration of ALA is typically related to acute intermittent porphyria, hereditary tyrosinemia, and lead poisoning. δ-Aminolevulinic acid produced in excess accumulates in a number of organs, causes oxidative damage, and often leads to cancer. Melatonin (N-acetyl-5-methoxytryptamine) is a well-known antioxidant, free radical scavenger, and exhibits anticarcinogenic properties. It protects DNA, lipids, and proteins from oxidative damage. The protective effects of melatonin against ALA-induced oxidation of guanine bases, lipid peroxidation, and alterations in membrane fluidity in several organs have been documented. There is an inverse relationship between melatonin and ALA concentrations in both experimental and clinical conditions of porphyria. The marked efficacy of melatonin in protecting against ALA-related oxidative stress, its oncostatic properties, and low toxicity constitute reasons to consider the use of this indoleamine as a co-treatment in patients suffering from disturbances related to ALA accumulation.

AB - δ-Aminolevulinic acid (ALA) is a precursor of haem. The increased concentration of ALA is typically related to acute intermittent porphyria, hereditary tyrosinemia, and lead poisoning. δ-Aminolevulinic acid produced in excess accumulates in a number of organs, causes oxidative damage, and often leads to cancer. Melatonin (N-acetyl-5-methoxytryptamine) is a well-known antioxidant, free radical scavenger, and exhibits anticarcinogenic properties. It protects DNA, lipids, and proteins from oxidative damage. The protective effects of melatonin against ALA-induced oxidation of guanine bases, lipid peroxidation, and alterations in membrane fluidity in several organs have been documented. There is an inverse relationship between melatonin and ALA concentrations in both experimental and clinical conditions of porphyria. The marked efficacy of melatonin in protecting against ALA-related oxidative stress, its oncostatic properties, and low toxicity constitute reasons to consider the use of this indoleamine as a co-treatment in patients suffering from disturbances related to ALA accumulation.

UR - http://www.scopus.com/inward/record.url?scp=0036198601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036198601&partnerID=8YFLogxK

U2 - 10.1081/CNV-120001154

DO - 10.1081/CNV-120001154

M3 - Article

VL - 20

SP - 276

EP - 286

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -